Tag
Aurobindo Pharma Limited
5 articles
Investor engagement is a key focus for Aurobindo Pharma as management participates in multiple conferences and meetings throughout September 2026. The company is actively engaging with investors through events hosted by J.P. Morgan, Bank of America, Emkay Global, Kotak, and ICICI Securities, both in group and one-on-one settings across India and Hong Kong. Aurobindo Pharma has consistently emphasized that no unpublished price-sensitive information will be disclosed during these interactions, adhering to regulatory compliance requirements with the BSE and NSE. These proactive investor relations efforts suggest a commitment to transparency and maintaining open communication with stakeholders as the company navigates the evolving pharmaceutical landscape.
Aurobindo Pharma Receives USFDA Approval for Perampanel
Aurobindo Pharma received USFDA final approval for Perampanel Tablets across six dosage strengths for epilepsy treatment.
The product has an estimated market size of $67 million and will be manufactur
Aurobindo Pharma Subsidiary Completes A1 Biochem Acquisition
Aurobindo Pharma's subsidiary Apitoria completed acquisition of A1 Biochem's Contract Research Services business.
Apitoria now holds 80% stake in A1 Biochem Labs India and 20% is held by former promot
Aurobindo Pharma Subsidiary Acquires A1 Biochem Labs LLC
Aurobindo Pharma's subsidiary Apitoria completes acquisition of A1 Biochem Labs LLC for USD 15.247 million in cash.
The acquisition expands Aurobindo's API business into contract research, creating a
Aurobindo Pharma Subsidiary A1 Labs Allots 20% Stake
Aurobindo Pharma's subsidiary Apitoria completed the allotment of a 20% stake in A1 Biochem Labs to its former promoter Dr. Rajendra Gadikota.
The transaction involved an infusion of ₹33.80 crore into
Aurobindo's Acrotech Launches ADQUEY Dermatology Drug in US
Acrotech Biopharma launches ADQUEY™, a novel topical PDE4 inhibitor for atopic dermatitis in US markets.
The product enters a US$1.3 billion market and marks Acrotech's entry into US dermatology thera